SILV.L
Global X Silver Miners UCITS ETF USD Acc
LSEUSDETF / FUND
DELAYED
Last price
47.20
▲ 0.35 (0.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
46.85
Day high
48.12
Day low
46.85
Volume
34.85K
Market cap
—
P/E (TTM)
0.19
52W range
25.49 – 57.97
Trailing performance
Returnvs SPY
1W
+10.57%
+11.9%
1M
+32.94%
+29.2%
3M
+9.91%
+6.8%
6M
-5.68%
-16.8%
YTD
+17.68%
+5.4%
1Y
+88.31%
+68.3%
3Y
+292.32%
+218.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Top holdings
| Symbol | Name | Weight | |
|---|---|---|---|
| WPM.TO | Wheaton Precious Metals Corp | 14.91% | |
| PAAS.TO | Pan American Silver Corp | 13.75% | |
| CDE | Coeur Mining Inc | 11.61% | |
| HL | Hecla Mining Co | 7.07% | |
| PE&OLES.MX | Industrias Penoles SAB de CV | 6.54% | |
| FRES.L | Fresnillo PLC | 4.34% | |
| BVN | Compania De Minas Buenaventura SAA ADR | 4.23% | |
| SSRM.TO | SSR Mining Inc | 3.89% | |
| 010130.KS | Korea Zinc Co Ltd | 2.45% | |
| EXK | Endeavour Silver Corp | 1.68% |
Sector exposure
Basic materials
99.81%
Consumer defensive
0.19%
Fund profile
Fund familyGlobal X
Category—
Legal typeExchange Traded Fund
Expense ratio0.00%
Turnover0.0%
Total net assets$15.29M
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SILV.L open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E0.19
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
43.90
+7.50% from price
SMA 20
40.52
+16.50% from price
SMA 50
38.69
+21.99% from price
SMA 100
41.23
+14.48% from price
SMA 200
42.15
+11.97% from price
EMA 12
43.33
+8.93% from price
EMA 26
41.04
+15.01% from price
EMA 50
40.19
+17.43% from price
RSI (14)
69.2
Neutral
MACD (12,26,9)
2.29
Hist 0.72
ATR (14)
2.02
4.27% of price
Realised vol 30D
57.6%
Annualised
Bollinger upper
48.60
20, 2σ
Bollinger lower
32.43
20, 2σ
50 / 200 cross
Death
38.69 vs 42.15
Trend bias
Above 200
+11.97%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.77
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
57.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.8%
Peak to trough
Max drawdown 5Y
-39.8%
Peak to trough
ATR 14
2.02
4.27% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
3 Unpopular Stocks We Steer Clear Of
StockStory · 9m ago
Oleria and Happiest Minds Partner to Accelerate Modern Identity Governance for AI-First Enterprises
ACCESS Newswire · 12m ago
Vicore Pharma to Present at the European Respiratory Society Congress 2026
ACCESS Newswire · 12m ago
Dollar trading near multi-month lows, restrained by debt nerves
Reuters · 12m ago
Billionaire Investor Stanley Druckenmiller Sold Broadcom, Intel, and Micron and Bought Another Chip Stock That Expects to Double Data Center Sales in 2027
Motley Fool · 22m ago
TME Pharma provides update on its activities
GlobeNewswire · 22m ago
American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals
Business Wire · 27m ago
Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors
Business Wire · 27m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.